How do I find a fractional CRO for a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

The Health System Procurement Committee Has Seven Layers of Veto Power

The buying committee for a healthcare technology solution is not a flat group of stakeholders - it is a cascading hierarchy where each layer can kill a deal without the previous layer knowing. The clinical champion (typically a department chair or nursing director) validates that your solution does not add documentation burden to their already overworked staff. The medical informatics officer checks whether your data schema maps to their existing FHIR or HL7 standards. The IT security team runs a 40-question vendor risk assessment that covers data encryption at rest and in transit, breach notification timelines, and subprocessor lists. The legal department negotiates a business associate agreement that indemnifies the hospital against any patient data exposure, even if caused by your cloud provider. The value analysis committee (a group of physicians, nurses, and administrators) evaluates your solution against competing internal projects using a weighted scoring matrix that includes clinical outcomes, cost savings, and implementation risk. The supply chain director checks whether your pricing aligns with their group purchasing organization's contracted rates. The CFO signs only after seeing a net present value calculation with a 15% internal rate of return over three years.

Deal sizes in healthcare technology follow a bimodal distribution. Point solutions that solve a single workflow problem (like automated prior authorization for imaging) close at $60,000-$120,000 annual contract value per hospital. Platform solutions that replace an existing system (like a new revenue cycle management module) close at $300,000-$800,000 per health system. Budget approval requires the clinical champion to secure a pilot budget from their operational fund (often $30,000-$60,000), then the CFO must approve the full rollout from capital expenditure. Deals stall at the value analysis committee stage because the hospital needs to compare your ROI against three other vendors, and that comparison takes 6-10 weeks. The second stall point is the security review, where a missing penetration test report or an ambiguous data retention policy can halt progress for a month. A fractional CRO must preempt these stalls by providing a completed security questionnaire and a value analysis template before the first demo.

The Sales Cycle Forces a Clinical Validation Loop That Most SaaS CROs Cannot Navigate

The healthcare technology sales cycle runs 9-18 months because the hospital requires proof that your solution works in their specific clinical environment. The motion is not a linear pipeline - it is a series of gates where each gate requires evidence from the previous gate. The fractional CRO must force a discovery process that uncovers the hospital's specific reimbursement pressure: is it the Hospital Readmissions Reduction Program penalties, the Merit-based Incentive Payment System adjustments, or the bundled payment penalties for joint replacements? Each pressure requires a different ROI calculation. Ramp time for a fractional CRO is 75-90 days, but they must arrive with a list of 25-35 target health systems where they already know the medical informatics director or the value analysis committee chair. Forecast behavior is unreliable until the fractional CRO has validated that each opportunity has passed the security review gate. A deal that is "in legal" means nothing if the security review is still pending, because the hospital's legal team will not finalize a contract without security sign-off.

Pipeline shape is a funnel with a narrow top and a slow middle. Most leads come from industry events like the American College of Healthcare Executives conference or the Healthcare Financial Management Association annual meeting, or from referrals from existing hospital clients. Leaks occur at three specific points. First, when the clinical champion changes jobs - 35% of healthcare deals collapse because the new champion wants to evaluate other vendors. Second, when the security review reveals that your data center is not HITRUST certified - hospitals increasingly require HITRUST certification for any solution that touches protected health information. Third, when the value analysis committee decides your solution is a "nice to have" rather than a "must have" - this happens when the ROI model does not tie to a specific penalty or reimbursement code. A fractional CRO must build pipeline with 4x coverage to account for these leaks, and they must enforce a rule that no deal enters the forecast until the security questionnaire has been submitted. The sales motion also forces a "clinical proof-of-concept" where your solution runs on a single unit (like the cardiology floor) for 60-90 days, measuring specific outcomes like time to discharge or reduction in duplicate lab orders. The fractional CRO must design this proof-of-concept with clear success metrics that the hospital's analytics team can validate.

The First 90 Days Require a Clinical Audit, Not Just a Sales Audit

A fractional CRO for healthcare technology must have personally closed deals with at least five different health systems, including at least one academic medical center and one community hospital. They should have a contact list of 75-100 people at the director level or above within hospital networks, and they must understand the difference between a 340B hospital's buying behavior versus a non-340B hospital. Their first 90 days follow a clinical-first plan.

Days 1-30: Conduct a clinical audit of your existing sales materials. The fractional CRO will review whether your case studies include specific metrics like reduction in average length of stay, decrease in 30-day readmission rates, or improvement in HCAHPS scores. They will interview your customer success team to understand which clinical workflows your product actually changes, and they will shadow a nurse or physician using your solution to understand the real-world friction points. They will also conduct 15-20 discovery calls with former prospects who chose a competitor, asking specifically why the competitor's clinical evidence was more compelling. They should produce a 40-page "Clinical Revenue Assessment" that maps your solution's impact to specific CMS quality measures and reimbursement codes.

Days 31-60: Build a clinical sales playbook that includes three distinct value narratives. The first is for the clinical champion, focused on workflow efficiency and patient outcomes, using data from your existing customers. The second is for the CFO, focused on ROI tied to specific reimbursement codes and penalty avoidance, with a spreadsheet model that the hospital's finance team can audit. The third is for the IT security team, focused on compliance certifications and data architecture, with a completed HITRUST self-assessment and a data flow diagram. The fractional CRO will also hire or onboard a clinical sales specialist - someone with a nursing or medical background who can speak the language of the clinical champion during demos. They will launch an outbound campaign targeting the top 25 health systems, using personalized outreach that references each hospital's publicly reported quality metrics from Hospital Compare or Leapfrog.

Days 61-90: Close the first deal or push two stalled opportunities through the value analysis committee. They will run a weekly "clinical pipeline review" that tracks not just deal stages but also which specific CMS quality measure each deal addresses. They will also establish a monthly "revenue and clinical outcomes" report that shows the correlation between closed deals and specific clinical metrics. They should provide a "go/no-go" recommendation at day 90 that includes an assessment of whether your product has enough clinical evidence to scale or whether you need a formal clinical trial.

The Reimbursement Dependency Creates a Unique Revenue Model Problem

Healthcare technology companies face a revenue model challenge that software companies in other industries do not: the hospital's willingness to pay depends on whether your solution helps them capture more reimbursement or avoid penalties. A fractional CRO must understand that the hospital's budget is not a simple operating expense line - it is tied to specific revenue cycle metrics. For example, a solution that reduces claim denials must show that it will increase the hospital's net revenue by a specific percentage, which requires the fractional CRO to understand denial rates, appeal success rates, and average reimbursement per claim. A solution that reduces readmissions must show that it will lower the hospital's readmission penalty, which requires the fractional CRO to understand the hospital's current readmission rate, the penalty percentage, and the average cost per readmission. This creates a revenue model where the fractional CRO must build a financial model that the hospital's CFO can audit, with assumptions that are defensible to the hospital's internal auditors. Most SaaS CROs cannot do this because they have never worked with reimbursement data. The fractional CRO must have experience building "value-based pricing" models where the hospital pays based on outcomes achieved, such as a percentage of avoided penalties or a per-member-per-month fee for population health solutions.

Sourcing and Vetting Requires a Clinical Reference Check, Not Just a Sales Reference Check

Do not hire a fractional CRO from a generalist sales recruiting firm. Instead, use three sourcing channels specific to healthcare technology. First, contact the venture partners at health-focused venture capital firms like Flare Capital, .406 Ventures, or Frist Cressey Ventures - these partners often have a network of former CROs from their portfolio companies. Second, reach out to the alumni networks of healthcare technology companies that have been acquired, such as the former sales leaders from Phytel (acquired by IBM Watson Health) or the former CROs from Evidation Health. Third, use the Healthcare Sales and Marketing Association's member directory, which includes sales leaders who have specifically worked in healthcare technology. During the interview, do not ask about general sales methodology. Instead, ask for a "clinical deal walkthrough" where the candidate describes a specific deal they closed, including the CMS quality measure that drove the purchase, the security review timeline, and the specific EHR integration required. Ask them to explain how they handled a situation where the hospital's IT security team required a data residency guarantee that your cloud provider could not meet. A red flag is a candidate who cannot name the specific CPT codes or DRG codes relevant to your product's clinical use case, or who cannot explain the difference between a HIPAA business associate agreement and a HIPAA covered entity agreement.

Compensation Must Include a Clinical Milestone Bonus, Not Just a Revenue Bonus

Fractional CROs for healthcare technology are compensated with a monthly retainer plus a bonus tied to clinical validation milestones, not just closed revenue. The retainer is $18,000-$28,000 per month for a 4-month engagement, with a 30-day termination clause. The bonus structure should include three tiers: $5,000 for completing a clinical value analysis template for your product, $10,000 for getting a deal through the security review gate, and 10% of first-year contract value for closed deals. Do not offer equity unless the fractional CRO is committed to converting to full-time after 6 months. The engagement should be structured as a "clinical sprint" with a 4-month duration and a mutual option to extend for another 3 months. The fractional CRO should provide a weekly "clinical deal tracker" that shows the status of each opportunity, the specific CMS quality measure it addresses, and the security review stage. They should also provide a monthly "board update" that includes a pipeline health report, a forecast accuracy analysis, and a clinical evidence gap assessment. If the fractional CRO cannot get a deal through the security review gate within the first 4 months, end the engagement and consider whether your product needs a clinical trial before you can sell to health systems.

FAQ

A question? How do I verify that a fractional CRO has actually sold to health systems and not just to physician practices? Ask for three reference calls with hospital CFOs or chief medical informatics officers, not with private practice administrators. Request that the candidate provide a redacted copy of a completed hospital security questionnaire they have submitted. Also ask for a sample value analysis committee presentation they have delivered. If they cannot provide a reference from a hospital with over 300 beds or a health system with multiple facilities, they likely have only sold to small practices.

A question? What if my product is a direct-to-consumer healthcare technology that hospitals do not buy? The fractional CRO must understand consumer healthcare acquisition, including HIPAA-compliant marketing automation, patient acquisition cost benchmarks, and insurance reimbursement for digital health services. The buying dynamic shifts to patient out-of-pocket spending or employer-sponsored wellness programs. The sales cycle is 3-6 months with a focus on user acquisition metrics and retention rates. The CRO should have experience with Facebook and Google healthcare advertising policies, which are more restrictive than general advertising.

A question? How do I handle a fractional CRO who wants to change my pricing to a per-member-per-month model? Do not change your pricing model without running a financial simulation that shows the impact on unit economics. Ask the fractional CRO to build a three-year financial model that compares your current pricing to the proposed model, including assumptions about adoption rates, churn, and implementation costs. Only approve the change if the model shows a 20% improvement in net revenue retention. If the fractional CRO cannot provide a defensible financial model, they are guessing.

A question? What are the warning signs a fractional CRO is not working out in healthcare technology? If they cannot schedule a meeting with a hospital's value analysis committee within 45 days, or if they avoid discussing specific CMS quality measures and reimbursement codes, they are not effective. Another red flag is if they try to use a generic SaaS sales methodology without adapting it to the clinical validation loop. A third sign is if they recommend lowering your price to compete with smaller vendors instead of building a stronger clinical ROI case. If two of these signs appear by day 60, end the engagement and consider whether your product needs a clinical evidence study before you can hire a sales leader.

Sources